急性呼吸窘迫综合征临床试验:挑战与机遇
今年是急性呼吸窘迫综合征(ARDS)首次描述50周年。本文回顾了ARDS临床试验的经验,重点讨论了未来改进临床试验设计以最大概率识别有益药物治疗的机会,包括针对特定亚组的预后和预测富集策略,以及预防性临床试验和早期治疗的设计。
要点
- 肺保护性通气(潮气量6 mL/kg预测体重,平台压<30 cm H2O)已降低ARDS死亡率。
- 神经肌肉阻滞和俯卧位通气进一步降低严重低氧血症ARDS患者死亡率。
- 液体保守治疗增加ARDS患者无呼吸机天数。
核心结论
- ARDS临床试验需采用预后和预测富集策略,基于严重程度和生物学特征靶向特定亚组患者,以提高识别有益药物治疗的可能性。
研究设计与样本
- 本文为综述,总结既往ARDS临床试验经验并讨论未来改进临床试验设计的机会。
主要发现
- 肺保护性通气(潮气量6 mL/kg预测体重,平台压<30 cm H2O)已降低ARDS死亡率。
- 神经肌肉阻滞和俯卧位通气进一步降低严重低氧血症ARDS患者死亡率,可能通过延长肺保护性通气的治疗效果。
- 液体保守治疗增加ARDS患者无呼吸机天数。
- 药理学治疗ARDS缺乏成功。
关键数值与推荐
- 肺保护性通气使用潮气量6 mL/kg预测体重和平台压<30 cm H2O。
- 减少ARDS临床试验异质性的方法包括使用生理学、影像学和生物学标准选择患者用于2期和3期试验。
临床怎么用
- 对严重低氧血症ARDS患者考虑神经肌肉阻滞和俯卧位通气。
- 采用液体保守治疗以增加无呼吸机天数。
- 未来临床试验可考虑预防性设计和在气管插管前早期治疗急性肺损伤。
局限性
- 药理学治疗ARDS缺乏成功。
- ARDS存在异质性,需富集策略靶向特定亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This year is the 50th anniversary of the first description of acute respiratory distress syndrome (ARDS). Since then, much has been learned about the pathogenesis of lung injury in ARDS, with an emphasis on the mechanisms of injury to the lung endothelium and the alveolar epithelium. In terms of treatment, major progress has been made in reducing mortality from ARDS with lung-protective ventilation, using a tidal volume of 6 mL per kg of predicted bodyweight and a plateau airway pressure of less than 30 cm H2O. In more severely hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have further reduced mortality, probably by extending the therapeutic effects of lung protective ventilation. Fluid-conservative therapy has also increased ventilator-free days in patients with ARDS. The lack of success of pharmacological therapies for ARDS, however, presents a continued challenge in the field. In addition to presenting a brief summary of previous experience with clinical trials in ARDS, we focus in this Review on future opportunities to improve clinical trial design to maximise the likelihood of identifying beneficial pharmacological therapies. In view of the heterogeneity in ARDS, both prognostic and predictive enrichment strategies are needed that target therapies toward specific subgroups of patients with ARDS on the basis of both severity and biology. Approaches to reducing heterogeneity in ARDS clinical trials include using physiological, radiographic, and biological criteria to select patients for both phase 2 and 3 trials. Additionally, interest is growing in the design of preventive clinical trials in ARDS and to initiate early treatment of patients with acute lung injury before the need for endotracheal intubation. We also present promising new approaches to treating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compounds with low-risk profiles that are already in routine clinical use for other clinical indications.
引用
- Matthay MA, McAuley DF, Ware LB, et al. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017. PMID: 28664851. doi:10.1016/S2213-2600(17)30188-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。